A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-nega...
Lay Description
Category
- Child Health
- Immune System
- Infections / Infectious Diseases
- IRB Number
- 20190414HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Diana Anzueto Guerra
(210) 567-5225
anzuetod@uthscsa.edu
Joseph Cantey
(210) 567-5225
cantey@uthscsa.edu
Principal Investigator
Joseph Cantey